La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

3SBio Dividende

Dividende contrôle des critères 3/6

3SBio est une société versant des dividendes avec un rendement actuel de 3.88% qui est bien couvert par les bénéfices.

Informations clés

3.9%

Rendement du dividende

36%

Ratio de distribution

Rendement moyen de l'industrie	1.2%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	HK$0.250
Résultat par action	HK$0.66
Prévisions de rendement du dividende à 3 ans	3.5%

Mises à jour récentes des dividendes

Recent updates

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: 1530 verse un dividende depuis moins de 10 ans et pendant cette période, les paiements ont été volatils.

Dividende croissant: Les paiements de dividendes de 1530 ont augmenté, mais la société n'a versé de dividendes que pendant 6 ans.

Rendement des dividendes par rapport au marché

3SBio Rendement des dividendes par rapport au marché

Comment le rendement du dividende de 1530 se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (1530)	3.9%
25% du marché (HK)	3.5%
25% du marché (HK)	8.3%
Moyenne du secteur (Biotechs)	1.2%
Prévisions des analystes dans 3 ans (1530)	3.5%

Dividende notable: Le dividende de 1530 ( 3.87% ) est supérieur à celui des 25 % des payeurs de dividendes les plus faibles du marché Hong Kong ( 3.52% ).

Dividende élevé: Le dividende de 1530 ( 3.87% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché Hong Kong ( 8.22% ).

Bénéfice distribué aux actionnaires

Couverture des revenus: Avec son taux de distribution relativement faible ( 35.7% ), les paiements de dividendes de 1530 sont bien couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Avec son ratio de distribution en espèces relativement faible ( 39.1% ), les paiements de dividendes de 1530 sont bien couverts par les flux de trésorerie.

3SBio Dividende

Dividende contrôle des critères 3/6

Informations clés

Mises à jour récentes des dividendes

Upcoming dividend of HK$0.25 per share

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Recent updates

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Consensus EPS estimates fall to CN¥0.52